Chads vasc score calculator

Author: o | 2025-04-24

Calculate CHADS-VASc Score and evaluate indication for anticoagulation Last Updated: . CHA2DS2-VASc Score Calculator Congestive Heart Failure Calculate CHADS-VASc Score and evaluate indication for anticoagulation Last Updated: CHA2DS2-VASc Score Calculator Congestive Heart Failure

Calculate CHADS-VASc Score and evaluate

And protected LMCA (patients with a history of previous CABG). Further calculations were performed based on the severity of CAD. Patients were divided into four subgroups: isolated LMCA narrowing, with additional 1-, 2- or 3-vessel disease (1-VD, 2-VD, 3-VD, respectively). The design of the study is very well conceived.In the overall cohort, EuroSCORE II as compared to ACEF and CHA2DS2-VASc, provided the best discriminative performance for the 30-day mortality (P=0.03 and PIn patients with unprotected LMCA, EuroSCORE II showed better discriminative performance than ACEF and CHA2DS2-VASc in short-term (P=0.051 and PPertinent conclusions.Reply: We thank for the kind words and remark regarding recent guidelines recommendations to use CHA2DS2-VA instead of CHA2DS2-VASc. To make our analysis up to date, we have now included CHADS-VA analyses in the manuscript. However, to remain maximal generalizability, we decided not to remove results investigating validation of CHA2DS2-VASc score – calculator widely used for the past 14 years.Now, readers can find information on the performance of four calculators in present manuscript.Changes: Please see changes in the Introduction, Methods, Results and Discussion section and new Figure 3 now included in the manuscript. Reviewer 3 Report Comments and Suggestions for AuthorsIn the study the authors established that EuroSCORE II showed good mortality prediction the short-term observation, its predicted risk should be interpreted with caution due to poor calibration. ACEF score and EuroSCORE II may be useful in long-term mortality prediction.Although the findings are impressive and practically useful, I would like to make some comments.1. The authors might discuss the patients-related factors incorporated into the EuroSCORE II, which had not been added to Table 1.2. ACEF score was developed for 30-day mortality after elective or emergency cardiac surgery, so it is not suitable for the long-term risk evaluation. Please, explaine this.3. CHA₂DS₂-VASc Score is avaiable for Atrial Fibrillation Stroke Risk,

Calculate CHADS-VASc Score and evaluate indication for

Compared to ACEF and CHA2DS2-VASc, provided the best discriminative performance for the 30-day mortality (P=0.03 and PIn patients with unprotected LMCA, EuroSCORE II showed better discriminative performance than ACEF and CHA2DS2-VASc in short-term (P=0.051 and P in the long-term EuroSCORE II and ACEF were better than CHA2DS2-VASc (P both two model comparisons). In the subgroup of post-CABG patients, EuroSCORE II and ACEF provided moderate 30-day mortality discriminative performance, as opposed to poor CHA2DS2-VASc discrimination. In the long-term, all of the analysed CPMs provided acceptable discriminative performance.Pertinent conclusions. Author Response The study presents actual data with a lot of clinical implications.The present study analyses data collected retrospectively from the BIA-LM Registry.In brief, the registry is a single-centre database of LMCA PCI performed in the Department of Invasive Cardiology, Medical University of Bialystok, Poland analyzing patients referred for surgical or conservative treatment during a period of 4 years, from 12.27.2008 to 02.21.2022.A final cohort of 851 individuals undergoing LMCA angioplasty were included into analysis. All analysed scores were recalculated for every patient enrolled in the study: EuroSCORE II using the interactive calculator (available at CHA2DS2-VASc as sum of 1 point for diagnosis of heart failure, hypertension, age between 65-74 years, diabetes mellitus, vascular disease, female gender and 2 points for age ≥75 years and prior stroke or transient ischemic attack, and ACEF as age divided by ejection fraction plus one if serum creatinine was ≥2 mg/dl.One mention I have concerning CHA2DS2-VASC Score. Since 30 august 2024 is not actual. After 2024ESC Guideline for atrial fibrillation, CHA2DS2-VA Score is used instead of CHA2DS2-VASc. = Congestive heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, prior stroke/transient ischaemic attack/arterial thromboembolism (2 points), vascular disease, age 65–74 years (score)Analyses were performed for the overall population, patients with unprotected LMCA (i.e., with no previous CABG)

CHADS VASC Calculator - BizCalcs.com

Risk evaluation. Please, explaine this.Reply 2: Thank you for the comment. Indeed, ACEF Score developed by Ranucci was initially used for in-hospital and 30-day after elective cardiac surgery moratlity prediction. It’s performance in this setting was validated multiple times before. Thus, the aim of our study was to seek for novel application of the well-known clinical prediction models.We investigated both short- and long-term prognostic value in patients undergoing PCI for significant LMCA stenosis. In the short-term, ACEF provided worse mortality prediction than EuroSCORE II, however, in the long-term observation ACEF showed the best discriminative performance amongst analysed calculators. Good long-term performance of ACEF score suggests that universal three factors may act as a surrogate for comorbidity burden and general health status. This may have clinical implications, as patients with higher ACEF scores may obtain more personalized post-procedure surveillance. Higher-risk patients can be identified for closer monitoring, targeted follow-up, and intensive secondary and tertiary prevention, such as intensification of guideline-directed medical therapy targeted at nephroprotection and heart failure with mildly reduced or reduced ejection fraction – treatment including ACE inhibitors, SLGT-2 inhibitors, and finerenone in selected individuals.Changes 2: Please see Discussion section modified.CHA₂DS₂-VASc Score is avaiable for Atrial Fibrillation Stroke Risk, so that is not corresponded to the aim of the study.Reply 3: Thank you for this comment, we are glad to clarify this issue. In fact, none of the three analysed calculators were initially developed for assessment of adverse cardiovascular events in patients undergoing coronary angioplasty. A number of CPMs were developed in order to facilitate decision-making in patients with coronary artery disease undergoing PCI, including anatomic SYNTAX, Mayo Clinic and NCDR or, combining anatomic conditions with clinical data SYNTAX II. However, the inclusion of many variables leading to higher accuracy at the expense of complexity and less bedside usefulness. Calculate CHADS-VASc Score and evaluate indication for anticoagulation Last Updated: . CHA2DS2-VASc Score Calculator Congestive Heart Failure Calculate CHADS-VASc Score and evaluate indication for anticoagulation Last Updated: CHA2DS2-VASc Score Calculator Congestive Heart Failure

CHADS VASC Calculator – BizCalcs.com

Colon. Reply: We thank for the time and effort invested in reviewing our manuscript. We have changed the title accordingly.Changes: Please see modified title of the paper. Reviewer 2 Report Comments and Suggestions for AuthorsThe study presents actual data with a lot of clinical implications.The present study analyses data collected retrospectively from the BIA-LM Registry.In brief, the registry is a single-centre database of LMCA PCI performed in the Department of Invasive Cardiology, Medical University of Bialystok, Poland analyzing patients referred for surgical or conservative treatment during a period of 4 years, from 12.27.2008 to 02.21.2022.A final cohort of 851 individuals undergoing LMCA angioplasty were included into analysis. All analysed scores were recalculated for every patient enrolled in the study: EuroSCORE II using the interactive calculator (available at CHA2DS2-VASc as sum of 1 point for diagnosis of heart failure, hypertension, age between 65-74 years, diabetes mellitus, vascular disease, female gender and 2 points for age ≥75 years and prior stroke or transient ischemic attack, and ACEF as age divided by ejection fraction plus one if serum creatinine was ≥2 mg/dl.One mention I have concerning CHA2DS2-VASC Score. Since 30 august 2024 is not actual. After 2024ESC Guideline for atrial fibrillation, CHA2DS2-VA Score is used instead of CHA2DS2-VASc. = Congestive heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, prior stroke/transient ischaemic attack/arterial thromboembolism (2 points), vascular disease, age 65–74 years (score)Analyses were performed for the overall population, patients with unprotected LMCA (i.e., with no previous CABG) and protected LMCA (patients with a history of previous CABG). Further calculations were performed based on the severity of CAD. Patients were divided into four subgroups: isolated LMCA narrowing, with additional 1-, 2- or 3-vessel disease (1-VD, 2-VD, 3-VD, respectively). The design of the study is very well conceived.In the overall cohort, EuroSCORE II as

CHADS-VASc Score as a Predictor of No- Reflow

So that is not corresponded to the aim of the study.4. The authors should explaine how many patients with AF were included in the analysis and why they used CHA₂DS₂-VASc Score for the evaluation of clinical outcomes after PCI.5. Please, extend the section Discussion and Conclusio taking into consideration the issues mentioned above. Author Response In the study the authors established that EuroSCORE II showed good mortality prediction the short-term observation, its predicted risk should be interpreted with caution due to poor calibration. ACEF score and EuroSCORE II may be useful in long-term mortality prediction.Although the findings are impressive and practically useful, I would like to make some comments.The authors might discuss the patients-related factors incorporated into the EuroSCORE II, which had not been added to Table 1.Reply 1: Thank you for this important suggestion.In our dataset we gathered all of the variables initially included in EuroSCORE II calculator. Actually, most of the variables incorporated into the EuroSCORE II are already included in Table 1., although some of them are not directly titled as in the original publication by Nashef et al. [1], e.g., patients with severe valvular disease were considered either 2- or more procedures, patients with STEMI were considered emergency procedure. Due to the low prevalence of selected variables, some of them were not included in the Table 1., however, now as the Reviewer has suggested, we have updated Table 1. with new selected data included in EuroSCORE II calculator.[1] Samer A.M. Nashef, François Roques, Linda D. Sharples, Johan Nilsson, Christopher Smith, Antony R. Goldstone, Ulf Lockowandt, EuroSCORE II, European Journal of Cardio-Thoracic Surgery, Volume 41, Issue 4, April 2012, Pages 734–745, 1: Please see Table 1. updated.ACEF score was developed for 30-day mortality after elective or emergency cardiac surgery, so it is not suitable for the long-term

Chads-Vasc-Score-Rechner online

Imaging (EACVI) [6]. The anticoagulation protocol during emergency department rhythm control relied on standard operation procedure (SOP) implemented within the ED but remained at the discretion of the attending physician. SOPs for anticoagulation protocol strictly followed guidelines of the ESC in their latest version at the time of presentation. Briefly patients with a CHA2DS2-VASC Score of ≥ 2 in men and ≥ 3 in women recieved anticoagulation. Patients with a score below the cut off recieved anticoagulation, if a cardioversion was planned and for 4 weeks after cardioversion. Thereafter anticoagulation was decided by the treating physician.Patients undergoing emergency PCI recieved appropriate antiplatelet treatment (aspirin, clopidogrel) other potent antiplatelet agents (prasugrel, ticagrelor) were only administered in the cathlab. In general OAC was administered as soon as possible.Unless appropriate anticoagulation was documented or the onset of AF was unequivocally recent, a transesophageal echocardiogram for exclusion of intracardiac thrombus was performed prior to cardioversion. The only exception was emergency cardioversion which could not be delayed.Statistical analysisContinuous variables were tested for normal distribution using the Kolmogorov–Smirnov test. Normally distributed data is presented as means (standard deviations, SD). Non-normally distributed data is presented as medians (25th, 75th percentiles, IQR). Kaplan–Meier estimates are shown as counts or percentages. Here, groups were compared with the log-rank test. For categorical variables groups were compared using chi-squared test or Fisher’s exact test. For continuous variables, unpaired Student’s t-test or Wilcoxon rank-sum test was used. A multivariate Cox proportional hazards regression was performed to determine predictors for outcome parameters. The. Calculate CHADS-VASc Score and evaluate indication for anticoagulation Last Updated: . CHA2DS2-VASc Score Calculator Congestive Heart Failure Calculate CHADS-VASc Score and evaluate indication for anticoagulation Last Updated: CHA2DS2-VASc Score Calculator Congestive Heart Failure